Boston Scientific Co. (NYSE:BSX) Stock Holdings Raised by Conning Inc.

Conning Inc. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 4.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,759 shares of the medical equipment provider’s stock after buying an additional 412 shares during the period. Conning Inc.’s holdings in Boston Scientific were worth $829,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. CVA Family Office LLC lifted its stake in Boston Scientific by 7.4% during the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock valued at $147,000 after purchasing an additional 131 shares during the last quarter. ST Germain D J Co. Inc. lifted its stake in Boston Scientific by 8.0% during the second quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock valued at $148,000 after purchasing an additional 143 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Boston Scientific by 2.0% in the 1st quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock valued at $512,000 after acquiring an additional 148 shares in the last quarter. Transcend Capital Advisors LLC lifted its position in shares of Boston Scientific by 2.2% in the 2nd quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 148 shares in the last quarter. Finally, KCM Investment Advisors LLC lifted its position in shares of Boston Scientific by 1.7% in the 1st quarter. KCM Investment Advisors LLC now owns 9,225 shares of the medical equipment provider’s stock valued at $632,000 after acquiring an additional 150 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.4 %

Shares of BSX traded down $0.31 during mid-day trading on Wednesday, hitting $79.52. 4,195,525 shares of the company’s stock were exchanged, compared to its average volume of 6,098,590. The firm has a fifty day moving average of $76.66 and a two-hundred day moving average of $72.61. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $80.02. The stock has a market cap of $116.66 billion, a price-to-earnings ratio of 67.08, a P/E/G ratio of 2.49 and a beta of 0.78. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. Boston Scientific’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.53 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the sale, the executive vice president now directly owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 20,949 shares of company stock valued at $1,583,395. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of several research analyst reports. Barclays upped their price target on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. The Goldman Sachs Group initiated coverage on shares of Boston Scientific in a research report on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target for the company. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Finally, TD Cowen upped their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $85.24.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.